Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 413Methotrexate 250Cytarabine 235Vincristine 192fludarabine phosphate 174Dexamethasone 171fludarabine 147Etoposide 143Peripheral Blood Stem Cell Transplantation 137Filgrastim 132Whole-Body Irradiation 118Mycophenolic Acid 116Busulfan 113Doxorubicin 110Mercaptopurine 109Tacrolimus 107Cyclosporine 95Radiotherapy 93Melphalan 93pegaspargase 90Rituximab 90Prednisone 88Asparaginase 87Daunorubicin 86Granulocyte Colony-Stimulating Factor 76blinatumomab 74Antilymphocyte Serum 71Calcium Dobesilate 69Clofarabine 58Thiotepa 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × BEBT-908 × Clear all
NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Ruijin Hospital

Phase 2 Not yet recruiting
23 enrolled
LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡